Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Progranulin prevents regulatory NK cell cytotoxicity against antiviral T cells
Anfei Huang, Prashant V. Shinde, Jun Huang, Tina Senff, Haifeng C. Xu, Cassandra Margotta, Dieter Häussinger, Thomas E. Willnow, Jinping Zhang, Aleksandra A. Pandyra, Jörg Timm, Sascha Weggen, Karl S. Lang, Philipp A. Lang
Anfei Huang, Prashant V. Shinde, Jun Huang, Tina Senff, Haifeng C. Xu, Cassandra Margotta, Dieter Häussinger, Thomas E. Willnow, Jinping Zhang, Aleksandra A. Pandyra, Jörg Timm, Sascha Weggen, Karl S. Lang, Philipp A. Lang
View: Text | PDF
Research Article Immunology Infectious disease

Progranulin prevents regulatory NK cell cytotoxicity against antiviral T cells

  • Text
  • PDF
Abstract

`NK cell–mediated regulation of antigen-specific T cells can contribute to and exacerbate chronic viral infection, but the protective mechanisms against NK cell–mediated attack on T cell immunity are poorly understood. Here, we show that progranulin (PGRN) can reduce NK cell cytotoxicity through reduction of NK cell expansion, granzyme B transcription, and NK cell–mediated lysis of target cells. Following infection with the lymphocytic choriomeningitis virus (LCMV), PGRN levels increased — a phenomenon dependent on the presence of macrophages and type I IFN signaling. Absence of PGRN in mice (Grn–/–) resulted in enhanced NK cell activity, increased NK cell–mediated killing of antiviral T cells, reduced antiviral T cell immunity, and increased viral burden, culminating in increased liver immunopathology. Depletion of NK cells restored antiviral immunity and alleviated pathology during infection in Grn–/– mice. In turn, PGRN treatment improved antiviral T cell immunity. Taken together, we identified PGRN as a critical factor capable of reducing NK cell–mediated attack of antiviral T cells.

Authors

Anfei Huang, Prashant V. Shinde, Jun Huang, Tina Senff, Haifeng C. Xu, Cassandra Margotta, Dieter Häussinger, Thomas E. Willnow, Jinping Zhang, Aleksandra A. Pandyra, Jörg Timm, Sascha Weggen, Karl S. Lang, Philipp A. Lang

×

Figure 3

PGRN decreases cyclin T1 and CDK9 expression in NK cells.

Options: View larger image (or click on image) Download as PowerPoint
PGRN decreases cyclin T1 and CDK9 expression in NK cells.
(A) Splenocyte...
(A) Splenocytes were treated with 1000 U/ml IL-2 and the cyclin T1/CDK9 inhibitor SNS-032 for 6 hours (concentration as indicated). Gzm B levels were measured by flow cytometry (n = 4). The left panel represents the frequency of Gzm B in NK cells, and the right panel represents the Gzm B MFI in NK cells. (B–F) Freshly isolated NK cells were treated with IL-2 and PGRN for 4 days. (B) The uptake of PGRN into NK cells was measured by Western blotting (n = 4). The right panel indicates quantification of the data. (C) Cyclin T1 and CDK9 mRNA levels were examined by qPCR (n = 6). Relative mRNA levels were normalized to Actin. (D) Cyclin T1 and CDK9 protein levels were examined by Western blotting (n = 7). The middle panel represents the quantification of cyclin T1; the right panel represents CDK9 quantification. (E) Cyclin T1 protein levels were examined by flow cytometry at day3 after IL-2 treatment (n = 6). The right panel represents the quantification of cyclin T1 MFI. (F) Cyclin T1 protein levels were examined by immunofluorescence (n = 3). The right panel represents the quantification of cyclin T1 by cyclin T1 MFI/DAPI MFI by ImageJ. Scale bars: 20 μm. (G) Isolated NK cells were treated by IL-2 with or without PGRN. The phospho-Ser2 RNA polymerase II frequency (pSer2-RII, upper panel) and MFI (lower panel) were measured by flow cytometry at the indicated time points (n = 6). Data in A–G show mean ± SEM. Each symbol represents an individual mouse. P values calculated by 2-way ANOVA (except for B, D, E, and F by Student’s t test); *P < 0.05; **P < 0.001; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts